Study of symptom improvement effect of Esomeprazole and vonoprazan in reflux esophagitis patients

Study of symptom improvement effect of Esomeprazole and vonoprazan in reflux esophagitis patients - The symptomatic improvement in reflux esophagitis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020170

Enrollment

Registered

2015-12-14

Start date

2015-08-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reflux esophagitis

Interventions

Esomeprazole 20mg orally once a day in the morning Vonoprazan 20mg orally once a day in the morning

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligible, enrolled patients were who had judged to be appropriate to start the treatment of PPIs defined by GOS questionnaire and who had judged having insufficient therapeutic effects also defined by GerdQ despite continuing the conventional PPIs for four weeks or more.

Exclusion criteria

Exclusion criteria: The patient that a serious heart, liver, renal function disorder, a patient developing a malignant neoplasm, a gastrointestinal tract resection, stomach esophagus junction rebuilding art, a patient having the past of the straying neurolysis, the combination taboo medicine of esomeprazole and vonoprazan

Design outcomes

Primary

Measure	Time frame
Improvement rates in reflux symptoms after 2 and 4 weeks of treatment	—

Secondary

Measure	Time frame
Change in reflux symptom score after treatment	—

Countries

Japan

Contacts

Public ContactIshihara shinichi

Ishihara Gastroenterology clinic Internalmedicine

ccy63890@yahoo.co.jp0877-63-6677

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026